IMMUNOMEDICS, INC.

300 American Road, Morris Plains, New Jersey 07950 • (201) 605-8200

NEWS RELEASE

IMMUNOMEDICS REPORTS IMPROVED F-18 LABELING OF PEPTIDES FOR PET IMAGING OF TUMORS

-- Results Given in Two Presentations at the 56th Annual Meeting of Society of Nuclear Medicine --

Toronto, Canada, June 15, 2009 - Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced further improvements on the Company's novel method for attaching fluorine-18 (F-18) to peptides, one of which has been successfully tested for the PET imaging of receptor-expressing tumors in animals.

"We believe these studies provide additional confirmation that the concept of using a chelate to capture metal-bound F-18 can provide a general, convenient and rapid method for labeling peptides for use in PET imaging, including peptide receptors expressed in cancer," stated Cynthia L. Sullivan, President and CEO. "Immunomedics is planning to out-license this new method, which is the subject of several patent applications, on a product-by-product basis, so as to make it widely available," Ms. Sullivan reiterated.

The Company recently reported a new way of preparing F-18 labeled peptides that are stable enough to be used for positron emission tomography or PET imaging, the most prominent imaging tools in diagnostic medicine. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2009_PDF/PR05182009A.pdf for more information on the labeling method). Current PET imaging relies on the increased uptake of F-18, most widely given as the sugar analog, F-18 fluoro-2-deoxyglucose (F-18 FDG), by cancer and other cells that have abnormal glucose metabolism. However, F-18 FDG uptake is also accelerated in rapidly-proliferating normal cells (such as bone marrow), which may lead to false-positive results and lower specificity.

The goal of the first study presented at the meeting was to improve efficiency and yields of the new labeling method. By manipulating the chemical structure of the group that F-18 attaches to in a peptide, scientists at Immunomedics were able to label a new peptide, IMP-467, with 87% yield. In addition, attaching F-18 to the peptide was rapid, requiring only 5 minutes. Studies in nude mice revealed that the radiolabeled peptide is stable.

In the second study, the labeling method was applied to the PET imaging of gastrin-releasing peptide receptors. Bombesin (BBN) is a small peptide that has a wide variety of pharmacologic effects, including the release of gastrointestinal hormones and control of gastrointestinal movements. Recently, there is evidence that increased BBN receptor expression is a marker for a variety of human cancers that include breast, gastric, pancreatic, prostate, ovarian and small-cell lung cancer.

~ more ~

Using the new labeling method, F-18 was attached to IMP-468, a BBN peptide that binds to gastrin-releasing peptide receptors, and studied in animals bearing human prostate cancer cells. Results showed that F-18-labeled IMP-468 specifically binds to the tumor and small intestine, and that it was stable for the duration of the study.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 134 patents issued in the United States and more than 300 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:

Dr. Chau Cheng
Associate Director, Investor Relations & Business Analysis
(973) 605-8200, extension 123
ccheng@immunomedics.com

###